Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amy Fowler

Internal Medicine Hazard, KY Doctor of Osteopathy

NPI 1801051891 CMS profile 217972

101 Town And Country Ln, Hazard, KY 41701

Open in the dashboard

General payments

$7,521

427 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Fowler of Hazard, KY is reported in the CMS Open Payments database as having received $7,521 across 427 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $495 23
2024 General $661 32
2023 General $914 60
2022 General $2,621 96
2021 General $1,180 83
2020 General $994 75
2019 General $657 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Fowler
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Amy Fowler were reported at $495. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Amy Fowler Internal Medicine median Middle half National median
2019 $657 $159 $48–$570 $163
2020 $994 $119 $33–$402 $114
2021 $1,180 $135 $37–$521 $132
2022 $2,621 $141 $42–$496 $149
2023 $914 $149 $45–$519 $160
2024 $661 $154 $47–$537 $164
2025 $495 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,085 9 payments
  2. Lilly USA, LLC $1,007 80 payments
  3. AbbVie, Inc. $818 49 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $518 32 payments
  5. GlaxoSmithKline, LLC. $500 45 payments
  6. Sanofi-Aventis U.S. LLC $376 26 payments
  7. AstraZeneca Pharmaceuticals LP $353 13 payments
  8. Merck Sharp & Dohme Corporation $341 30 payments
  9. Amgen Inc. $329 19 payments
  10. Novo Nordisk Inc $243 21 payments
  11. Other $1,951 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,630 419 payments
  2. Travel and Lodging $820 4 payments
  3. Education $71 4 payments
Products named General payments · program years 2019–2025
  1. INPEN SMART INSULIN DELIVERY SYSTEM $1,085 9 payments
  2. TRULICITY $496 37 payments
  3. TRELEGY ELLIPTA $476 43 payments
  4. JARDIANCE $429 27 payments
  5. MAVYRET $317 17 payments
  6. FARXIGA $312 10 payments
  7. UBRELVY $309 20 payments
  8. EMGALITY $281 27 payments
  9. STEGLATRO $237 23 payments
  10. Repatha $223 13 payments
  11. Other $5,546 371 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 200 drugs

Part D claims

20,148

Median for Internal Medicine: 777

Drug cost

$1,826,940

Median for Internal Medicine: $73,373

Branded share of claims

26.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 270 $275,823
Mounjaro Tirzepatide Brand 201 $214,245
Jardiance Empagliflozin Brand 213 $189,032
Farxiga Dapagliflozin Propanediol Brand 246 $188,578
Eliquis Apixaban Brand 186 $170,001
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 133 $92,382
Trulicity Dulaglutide Brand 66 $72,877
Leqvio Inclisiran Sodium Brand 17 $55,312
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 58 $43,865
Entresto Sacubitril/Valsartan Brand 48 $39,135

The 10 drugs with the highest cost, of 200 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$63,673

Medicare's payments for the services billed

Medicare patients

235

Average age 73

Services billed

1,005

135 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 63%
Arthritis 61%
Diabetes 58%
Ischemic heart disease 55%
Heart failure 47%
Depression 45%
Chronic kidney disease 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $136
$136 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $48
  • Lundbeck LLC $16
$64 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $57
$57 — —
Auvelity
  • Axsome Therapeutics, Inc. $54
$54 — —
MOUNJARO
  • Lilly USA, LLC $48
$48 201 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

427 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record